Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159812 | 0.90 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL15688800 | 0.84 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL3235365 | 0.82 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL11354103 | 0.82 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6KMT2ACYP11B1 | |
| SCHEMBL306232 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL307542 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL3318872 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL4873932 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL309621 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP3A4 | |
| Hydrochloric Acid SCHEMBL11358575 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6KMT2ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849023-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-20100144812-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole | WYETH LLP (US) | 2010-06-10 | — | — | US | disclosed |
| US-7674813-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole | WYETH (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1709003-B1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | WYETH CORP (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080249150-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | WYETH (US) | 2008-10-09 | — | — | US | disclosed |
| US-7399778-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole | WYETH (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1709003-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | Wyeth (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073198-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | WYETH (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050171180-A1 | Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| EP-0421227-B1 | 1-Hydroxy-1,2,4-triazole derivatives and fungicides containing them and growth regulators | BASF AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| EP-0421227-A2 | 1-Hydroxy-1,2,4-triazole derivatives and fungicides containing them and growth regulators | BASF Aktiengesellschaft (DE) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144812-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole | APP, IAPP, PARK7 | CYP19A1 3074/4885HDAC1 3504/4885HDAC6 3336/4885 |
| US-20080249150-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | APP, IAPP, PARK7 | CYP19A1 3074/4885HDAC1 3504/4885HDAC6 3336/4885 |
| US-20050171180-A1 | Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole | IAPP, APP, CBR3 | CYP19A1 1070/4885HDAC1 3987/4885HDAC6 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.